The potential rescheduling of cannabinoids, particularly at the federal level, read more is generating considerable excitement within the industry. A shift away from Schedule I status, often considered as outdated and hindering progress, could unlock significant avenues for businesses. Reduced regulatory burdens, alongside greater access to banking